U.S. Markets closed

Nektar Therapeutics (NKTR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.6800-0.2300 (-4.68%)
At close: 04:00PM EDT
4.5300 -0.15 (-3.21%)
After hours: 04:34PM EDT

Nektar Therapeutics

455 Mission Bay Boulevard South
San Francisco, CA 94158
United States
415 482 5300

Full Time Employees740

Key Executives

NameTitlePayExercisedYear Born
Mr. Howard W. RobinCEO, Pres & Director2.14M5.01M1953
Mr. Mark A. WilsonSr. VP, Gen. Counsel & Sec.798.26k56.91k1972
Dr. Jonathan Zalevsky Ph.D.Sr. VP & Chief R&D Officer1.16MN/A1975
Mr. John P. NorthcottSr. VP & Chief Commercial Officer1.07MN/A1978
Ms. Jillian B. ThomsenSr. VP & CFON/AN/A1966
Mr. Robert BacciSr. VP of HR and FacilitiesN/AN/AN/A
Ms. Jennifer RuddockSr. VP of Strategy & Corp. AffairsN/AN/AN/A
Dr. Mary Tagliaferri L.Ac., M.D.Sr. VP & Exec. Clinical FellowN/AN/A1966
Dr. Brian L. Kotzin M.D.Chief Medical Officer & Sr. VPN/AN/A1949
Dr. Kevin BrodbeckSr. VP of ManufacturingN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; phase 1/2A clinical trial to treat squamous cell carcinoma of the head and neck; phase 1/2 clinical trial for the treatment of solid tumors; and phase 1B clinical trial to treat COVID-19. It is also developing NKTR-358, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer and colorectal cancer; and NKTR-262, a toll-like receptor agonist that is in phase 1/2 clinical trial to treat solid tumors, as well as various other drug candidates. The company has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. Nektar Therapeutics was incorporated in 1990 and is headquartered in San Francisco, California.

Corporate Governance

Nektar Therapeutics’s ISS Governance QualityScore as of July 1, 2022 is 4. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 3; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.